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ail address: KIMHS54@yuhs.ac (H.-S. Kim).a b s t r a c tBackground: We compared the diagnostic performances of two newly introduced fully
automated multiple allergen simultaneous tests (MAST) analyzers with two conventional
MAST assays.
Methods: The serum samples from a total of 53 and 104 patients were tested for food
panels and inhalant panels, respectively, in four analyzers including AdvanSure AlloScreen
(LG Life Science, Korea), AdvanSure Allostation Smart II (LG Life Science), PROTIA Allergy-
Q (ProteomeTech, Korea), and RIDA Allergy Screen (R-Biopharm, Germany). We compared
not only the total agreement percentages but also positive propensities among four
analyzers.
Results: Evaluation of AdvanSure Allostation Smart II as upgraded version of AdvanSure
AlloScreen revealed good concordance with total agreement percentages of 93.0% and
92.2% in food and inhalant panel, respectively. Comparisons of AdvanSure Allostation
Smart II or PROTIA Allergy-Q with RIDA Allergy Screen also showed good concordance
performance with positive propensities of two new analyzers for common allergens
(Dermatophagoides farina and Dermatophagoides pteronyssinus). The changes of cut-off
level resulted in various total agreement percentage fluctuations among allergens by
different analyzers, although current cut-off level of class 2 appeared to be generally
suitable.
Conclusions: AdvanSure Allostation Smart II and PROTIA Allergy-Q presented favorable
agreement performances with RIDA Allergy Screen, although positive propensities were
noticed in common allergens.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The detection of allergen-specific IgE, along with the patient’s chief complaints and medical history, is diagnostically
valuable for allergic diseases, such as allergic rhinitis, atopic dermatitis, and asthma [1,2]. Although in vivo skin test has been
traditionally used in the clinical environments, there are several limitations of in vivo skin test including error-prone resultser B.V. This is an open access article under the CC BY license
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and the lack of standardization for protocols [3,4]. Therefore, in vitro allergen-specific IgE measurements have been de-
veloped using various principles of radioimmunoassay, enzyme immunoassay, fluorescent enzyme immunoassay, im-
munoblot, and chemiluminescent assay [5–7].
Among the commercially available in vitro allergy tests, multiple allergen simultaneous tests (MAST) have been con-
tinuously developed with the improvements in smaller amounts of serum consumption, shorter turnaround time, and wider
spectrum of allergens included in the test [6,8–12]. Since the difference in prevalence of allergic diseases according to age,
sex, and ethnicity is prominent, the selection of multiple allergen screening panels should be modified in the context of
geographical regions and race of the target populations [13–15]. At the same time, the change of environmental substances
in modern society must be considered for the progressive development of MAST assays [16].
Moreover, there is no appropriate medical evidence to define any assay as the standardized reference method due to
variability of allergen original materials, extraction methods, attachment processes, and detection techniques [5]. Therefore,
it is very difficult to analyze true sensitivity, specificity, positive predictive value, and negative predictive value of a specific
MAST assay. Nevertheless, actual comparison of newMAST assay with currently used MAST assays can appropriately provide
important information in the practical clinical settings.
Recently, two fully automated analyzers with high-throughput were developed and introduced in the market; AdvanSure
Allostation Smart II which is the upgraded version of previous AdvanSure AlloScreen by LG Life Science, and PROTIA Allergy-
Q which was newly developed by ProteomeTech. Herein, we compared the diagnostic performances of these assays with
two most commonly used MAST assays in Korea, today. In addition, we evaluated propensity of each assay to give positive
results for certain allergen, which we defined as “positive propensity”.2. Methods
2.1. Study participants
We randomly selected the study samples from MAST assay requested serum samples of patients who visited Severance
Hospital with symptoms of allergy including urticaria, sneezing, and itching for diagnosis of allergic disease in all age ranges.
Additionally, we excluded patients with chronic comorbid diseases such as autoimmunity, malignancy, chronic infection,
and other immune-related diseases. Since two different panels were evaluated, we classified patients into two groups so
that appropriate panel could be tested based on clinical symptoms and medical records. Due to the variety of allergen types
included in the panel of four assays and lack of sufficient sample volume in some patients, different samples were analyzed
by different numbers of analyzers with various combinations of allergens. Therefore, only pairs of matched allergens by the
same sample were compared among four analyzers.
2.2. In vitro allergen-specific IgE measurements
Serum aliquots were tested by four different systems; AdvanSure AlloScreen (LG Life Science, Seoul, Korea), AdvanSure
Allostation Smart II (LG Life Science, Seoul, Korea), PROTIA Allergy-Q (ProteomeTech, Seoul, Korea), and RIDA Allergy Screen
(R-Biopharm, Darmstadt, Germany). All the test procedures were performed following the manufacture’s instruction. Al-
though detection ranges were various among four analyzers, results were identically classified into 7 levels and were in-
terpreted as class 0–6 in all analyzers (Table 1).Table 1
Specifications of four different MAST analyzers.
AdvanSure AlloScreen AdvanSure Allostation Smart II PROTIA Allergy-Q RIDA Allergy Screen
Manufacturer LG Life Science (Korea) LG Life Science (Korea) ProteomeTech (Korea) R-Biopharm (Germany)
Instrument AdvanSure™ Allostation AdvanSure™ Allostation Smart II Q-station AlleRoboT
Reagent AdvanSure™ Alloscreen AdvanSure™ Alloscreen PROTIA™ Allergy-Q AlleisaScreens
Principle Immunoblot Immunoblot Immunoblot Immunoblot
Class stratification Class 0–6 Class 0–6 Class 0–6 Class 0–6
Degree of automation Semi automation Full automation Full automation Full automation
Number of antigens
-Total (common) 60 (20) 90 (30) 70 (18) 80 (40)
-Food panel 40 60 44 60
-Inhalant panel 40 60 44 60
Minimal sample volume (μl) 100 250 120 800
Tested sample volume (μl) 100 100 50 300
Number of strips utilized 2 2 1 2
Capacity or number of tests per run 24 30 48 36
Analysis time (hr) 3.5 4.0 4.0 3.8
Analysis time per sample (min) 8.75 8 5 6.3
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We compared a pair of analyzers each time in order to maximize the comparison efficiency because different allergen
lists are available by four analyzers. Furthermore, we focused on comparison of two specific analyzers (AdvanSure Al-
loScreen versus AdvanSure Allostation Smart II), because AdvanSure Allostation Smart II is the upgraded version of Ad-
vanSure AlloScreen, both of which are developed by the same manufacturer (LG Life Science). Afterwards, we compared two
newly introduced analyzers (i.e. AdvanSure Allostation Smart II and PROTIA Allergy-Q) with currently widely utilized assay
(RIDA Allergy Screen) as reference values.
2.4. Comparison among different cut-off levels for positive interpretation
No standardized specific cut-off level for positive result is defined worldwide until today [17]. Moreover, previous studies
which compared various MAST assays utilized different cutoff levels. For instance, several studies used class 1 as the cutoff
level for positive results [8,11,12], whereas class 2 was adopted as the cutoff level for positive results in other studies
[6,10,32]. Considering the natural characteristics of semi-quantitative results in MAST assays, comparison of different cut-off
levels in the paired results might provide clinical clues for more precise diagnostic interpretation. Therefore, we applied cut-
off levels of class 1, class 2, and class 3 as minimal requirement for positive results for all comparison analyses.
2.5. Statistical analysis
We analyzed the concordance degree by calculating total agreement percentage following the same methodology used in
a previous study [18]; total agreement percentage¼(total number of resultsnumber of discrepancies)100/total number
of results. Additionally, concordant positive rates were calculated with the proportions of agreement for positive responses
because low frequency of positive results can affect the total agreement percentage. Furthermore, agreement of detection
results between two analyzers was determined by Cohen's kappa analysis [19]. Finally, the presence of propensity toward
positive results in specific assay for certain allergen was determined when the difference between discrepant results ac-
counted for over 10% of all pairs. For example, when assay A and assay B are compared for allergen C, [(number of samples
with A positive, B negative result)(number of samples with A negative, B positive result)]100/ total number of results
Z10% can be interpreted as the positive propensity of assay A for allergen C compared to assay B.
For all statistical analyses, we used MedCalc 11.0 (MedCalc Software, Belgium) and SPSS 18.0 (SPSS Inc., Chicago, IL).3. Results
3.1. Characteristics of study participants and paired sets
The serum samples from a total of 53 and 104 patients were tested for food panel and inhalant panel in this study.
Characteristics of study participants are summarized in Table 2. Although several patients presented multiple allergicTable 2
Characteristics of study participants.
Food panel Inhalant panel
Total number 53 104
Demographic characteristics
Number of male (%) 21 (39.6) 56 (53.8)
Age, median [1Q, 3Q] 32 [9,55] 35 [20.8, 56.5]
Age, range 1–85 5–78
Number of pediatric patients (%)a 16 (30.2) 24 (23.1)
Clinical symptoms and signs
Urticaria (%) 32 (60.4) 3 (2.9)
Dermatitis (%) 14 (26.4) 1 (1.0)
Allergic rhinitis (%) 5 (9.4) 87 (83.7)
Allergic bronchitis (%) 1 (1.9) 4 (3.8)
Asthma (%) 2 (3.8) 5 (4.8)
Anaphylaxis or angioedema (%) 6 (11.3) 1 (1.0)
Others (%) 8 (15.1)b 4 (3.8)c
Matched pairs in each comparison
AlloScreen vs. Allostation Smart II 43 90
Allostation Smart II vs. RIDA 30 79
Allergy-Q vs. RIDA 40 93
a Pediatric patients are defined as individuals with age o20 years.
b Others include xerotic eczema, erythema multiforme, drug eruption, and insect bite.
c Others include adenoid vegetation, chronic sinusitis, and sleep apnea.
Table 3
Comparison between AdvanSure AlloScreen and upgraded AdvanSure Allostation Smart II using cutoff value of class 2.
Allergen Food panel Inhalant panel
N¼43 N¼90
Agreement (%) Kappa index Kappa index (95% CI) Concordant positive rate (%) Agreement (%) Kappa index Kappa index (95% CI) Concordant positive rate (%)
Acacia 100.0 1.00 (1.00 to 1.00) 1.1
Alternaria alternata 100.0 1.00 (1.00 to 1.00) 11.6 100.0 1.00 (1.00 to 1.00) 3.3
Ash mix 100.0 1.00 (1.00 to 1.00) 1.1
Aspergillus fumigatus 100.0 1.00 (1.00 to 1.00) 1.1
Bermuda grass 97.8 0.74 (0.39 to 1.08) 3.3
Barley meal 97.7 0.66 (0.03 to 1.28) 2.3
Beef 100.0 1.00 (1.00 to 1.00) 2.3
Birch-Alder mix 97.7 0.79 (0.39 to 1.19) 4.7 96.7 0.38 (0.17 to 0.93) 1.1
Buck-wheat 100.0 1.00 (1.00 to 1.00) 2.3
Candida albicans 100.0 NA 0.0
Cat 95.3 0.64 (0.18 to 1.10) 4.7 92.2 0.50 (0.18 to 0.81) 4.4
Cheddar cheese 100.0 NA 0.0
Chicken 100.0 NA 0.0
Citrus mix 100.0 1.00 (1.00 to 1.00) 2.3
Cladosporium herbarum 97.7 0.00 (0.00 to 0.00) 0.0 98.9 0.66 (0.04 to 1.28) 1.1
Cockroach 97.7 0.79 (0.39 to 1.19) 4.7 97.8 0.74 (0.39 to 1.09) 3.3
Codfish 100.0 1.00 (1.00 to 1.00) 2.3
Crab 93.0 0.54 (0.10 to 0.99) 4.7 96.7 0.39 (0.15 to 0.93) 1.1
D. farinae 95.3 0.91 (0.78 to 1.03) 48.8 100.0 1.00 (1.00 to 1.00) 35.6
D. pteronyssinus 100.0 1.00 (1.00 to 1.00) 51.2 95.6 0.91 (0.81 to 1.00) 35.6
Dandelion 98.9 0.66 (0.04 to 1.28) 1.1
Dog 93.0 0.38 (0.16 to 0.91) 2.3 97.8 0.01 (0.03 to 0.00) 0.0
Egg white 100.0 1.00 (1.00 to 1.00) 2.3 100.0 NA 0.0
Garlic 97.7 0.79 (0.39 to 1.19) 4.7
Goldenrod 98.9 0.66 (0.04 to 1.28) 1.1
Hazelnut 98.9 0.66 (0.04 to 1.28) 1.1
House dust 93.0 0.82 (0.63 to 1.01) 23.3 93.3 0.84 (0.72 to 0.96) 26.7
Japanese cedar 98.9 0.66 (0.04 to 1.28) 1.1
Japanese Hop 100.0 1.00 (1.00 to 1.00) 2.3 98.9 0.66 (0.04 to 1.28) 1.1
Mackerel 97.7 0.66 (0.03 to 1.28) 2.3 100.0 NA 0.0
Milk 100.0 1.00 (1.00 to 1.00) 2.3 96.7 0.81 (0.59 to 1.02) 7.8
Mugwort 95.3 0.48 (0.14 to 1.10) 2.3 100.0 1.00 (1.00 to 1.00) 1.1
Oak white 97.7 0.66 (0.03 to 1.28) 2.3 98.9 0.66 (0.04 to 1.28) 1.1
Onion 100.0 1.00 (1.00 to 1.00) 2.3
Orchard grass 96.7 0.56 (0.12 to 1.00) 2.2
Oxeye daisy 98.9 0.66 (0.04 to 1.28) 1.1
Peach 97.7 0.66 (0.03 to 1.28) 2.3 97.8 0.49 (0.11 to 1.09) 1.1
Peanut 100.0 1.00 (1.00 to 1.00) 2.3
Penicillium notatum 100.0 1.00 (1.00 to 1.00) 2.2
Pigweed 100.0 1.00 (1.00 to 1.00) 2.2
Pine 100.0 1.00 (1.00 to 1.00) 1.1
Poplar mix 100.0 1.00 (1.00 to 1.00) 1.1
Pork 95.3 0.02 (0.06 to 0.01) 0.0
Ragweed 97.7 0.79 (0.39 to 1.19) 4.7 94.4 0.26 (0.18 to 0.70) 1.1
Reed 97.8 0.79 (0.51 to 1.07) 4.4
Rice 97.7 0.66 (0.03 to 1.28) 2.3
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Table 3 (continued )
Allergen Food panel Inhalant panel
N¼43 N¼90
Agreement (%) Kappa index Kappa index (95% CI) Concordant positive rate (%) Agreement (%) Kappa index Kappa index (95% CI) Concordant positive rate (%)
Russian thistle 96.7 0.65 (0.29 to 1.01) 3.3
Rye pollens 97.7 0.79 (0.39 to 1.19) 4.7 95.6 0.65 (0.33 to 0.96) 4.4
Salmon 100.0 1.00 (1.00 to 1.00) 2.3
Sallow willow 94.4 0.27 (0.15 to 0.70) 1.1
Shrimp 93.0 0.54 (0.10 to 0.99) 4.7 95.6 0.32 (0.16 to 0.80) 1.1
Soy bean 100.0 1.00 (1.00 to 1.00) 2.3 98.9 0.00 (0.00 to 0.00) 0.0
Sweet vernal grass 97.8 0.82 (0.58 to 1.06) 5.6
Sycamore mix 98.9 0.66 (0.04 to 1.28) 1.1
Timothy grass 97.8 0.79 (0.51 to 1.07) 4.4
Tomato 100.0 1.00 (1.00 to 1.00) 2.3
Tuna 100.0 NA 0.0
Wheat flour 97.7 0.79 (0.39 to 1.19) 4.7
Yeast, bakers 100.0 NA 0.0
NA: Not available.
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Table 4
Comparison of two new fully automated analyzers with RIDA Allergy Screen as a reference using cutoff level of class 2.
Allergen AdvanSure Smart II vs. RIDA PROTIA Allergy-Q vs. RIDA
Food panel Inhalant panel Food panel Inhalant panel
N¼30 N¼79 N¼40 N¼93
Agreement (%) Concordant
positive rate
(%)
Agreement (%) Concordant
positive rate
(%)
Agreement (%) Concordant
positive rate
(%)
Agreement (%) Concordant
positive rate
(%)
Acacia 100.0 1.3 97.8 0.0
Alternaria
alternata
100.0 16.7 93.7 1.3 100.0 12.5 93.5 0.0
Anchovy 100.0 0.0
Ash mix 100.0 1.3 96.8 0.0
Aspergillus
fumigatus
93.3 0.0 97.5 0.0 97.8 0.0
Banana 100.0 0.0
Barley meal 96.7 0.0 95.0 0.0
Beef 96.7 0.0 97.5 0.0
Bermuda grass 98.7 1.3 96.8 1.1
Birch-Alder
mix
96.7 3.3 96.2 0.0 97.5 0.0 92.5 2.2
Bromelain
(CCD)
93.3 0.0 92.4 1.3
Buck-wheat 100.0 0.0 95.0 0.0
Candida
albicans
100.0 0.0 100.0 0.0
Cat 96.7 0.0 88.6 2.5 97.5 0.0 93.5 2.2
Cheddar cheese 100.0 0.0 100.0 0.0
Chestnut 96.7 0.0 100.0 0.0
Chicken 100.0 0.0 100.0 0.0
Citrus mix 100.0 0.0 97.5 0.0
Cladosporium
herbarum
100.0 0.0 96.2 0.0 97.8 0.0
Clam 100.0 0.0 100.0 0.0
Cockroach 96.7 3.3 97.5 2.5 92.5 5.0 95.7 2.2
Codfish 96.7 0.0 100.0 0.0
Crab 93.3 0.0 100.0 0.0 85.0 0.0 94.6 0.0
Cucumber 100.0 0.0
D. farinae 76.7 26.7 77.2 12.7 76.7 30.0 82.8 11.8
D.
pteronyssinus
80.0 26.7 75.9 13.9 90.0 22.5 89.2 12.9
Dandelion 100.0 1.3 96.8 2.2
Dog 96.7 0.0 97.5 0.0 87.5 5.0 97.8 2.2
Egg white 100.0 3.3 98.7 0.0 100.0 7.5 97.8 0.0
Garlic 100.0 0.0 95.0 0.0
Goldenrod 97.5 1.3 95.7 0.0
Hazelnut 100.0 1.3 98.9 1.1
House dust 73.3 0.0 69.6 0.0 78.5 0.0
Japanese cedar 98.7 0.0 100.0 1.1
Japanese Hop 100.0 0.0 98.7 1.3 100.0 0.0 96.8 0.0
Kiwi 100.0 0.0 100.0 0.0
Latex 98.7 0.0 96.8 0.0
Mackerel 96.7 0.0 100.0 0.0 95.0 0.0 98.9 0.0
Mango 100.0 0.0
Milk 100.0 0.0 86.1 2.5 100.0 0.0 93.5 0.0
Mugwort 96.7 0.0 98.7 0.0 100.0 0.0 98.9 1.1
Mussel 100.0 0.0
Oak white 100.0 3.3 98.7 0.0 100.0 2.5 96.8 0.0
Onion 100.0 0.0
Orchard grass 100.0 1.3 97.8 1.1
Oxeye daisy 100.0 1.3 100.0 2.2
Peach 96.7 0.0 97.5 1.3 100.0 0.0 97.8 0.0
Penicillium
notatum
96.2 0.0 97.8 0.0
Pigweed 100.0 1.3 98.9 1.1
Pine 98.7 0.0 98.9 0.0
Poplar mix 98.7 0.0 97.8 1.1
Peanut 100.0 0.0 100.0 0.0
Pork 96.7 0.0 95.0 0.0
Potato 100.0 0.0 97.5 0.0
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Table 4 (continued )
Allergen AdvanSure Smart II vs. RIDA PROTIA Allergy-Q vs. RIDA
Food panel Inhalant panel Food panel Inhalant panel
N¼30 N¼79 N¼40 N¼93
Agreement (%) Concordant
positive rate
(%)
Agreement (%) Concordant
positive rate
(%)
Agreement (%) Concordant
positive rate
(%)
Agreement (%) Concordant
positive rate
(%)
Pupa, silk
cocoon
90.0 0.0 90.0 0.0
Rabbit 98.7 0.0
Ragweed 93.3 0.0 100.0 2.5 97.5 0.0 98.9 2.2
Redtop, bent
grass
100.0 1.3
Reed 96.2 0.0 97.8 0.0
Rice 100.0 0.0 95.0 0.0
Russian thistle 98.7 1.3 97.8 1.1
Rye pollens 100.0 0.0 93.7 2.5 95.0 0.0 98.9 2.2
Sallow willow 100.0 1.3 97.8 2.2
Salmon 96.7 0.0 100.0 0.0
Shrimp 96.7 6.7 94.9 0.0 95.0 0.0 100.0 0.0
Soy bean 100.0 0.0 100.0 0.0 100.0 0.0 100.0 0.0
Storage mite 86.7 6.7 89.9 10.1 90.3 11.8
Sweet vernal
grass
94.9 1.3
Sycamore mix 100.0 1.3 100.0 2.2
Timothy grass 94.9 1.3 97.8 2.2
Tomato 100.0 0.0 97.5 0.0
Tuna 100.0 0.0 100.0 0.0
Wheat flour 93.3 0.0 90.0 0.0
Yeast, bakers 100.0 0.0 100.0 0.0
Yellow jacket
(wasp)
96.2 0.0
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frequent clinical symptoms for participants in inhalant panel. As mentioned earlier, different numbers of matched pairs
were compared in each comparison analysis among four analyzers.
3.2. Comparison between AdvanSure AlloScreen and AdvanSure Allostation Smart II for evaluation of upgrade
When we compared qualitative results between AdvanSure AlloScreen and AdvanSure Allostation Smart II, we used class
2 as the cut-off level for positive result since the manufacturer suggested the possibility of class 1 result indicating in-
sufficient clinical significance to trigger allergic progression. A total of 43 and 90 paired serum samples were tested for 39
and 41 allergens in food and inhalant panel, respectively (Table 3). All allergens showed total agreement percentages over
93.0% and 92.2% in food and inhalant panel, respectively, which indicates good concordance between old and new versions
of AdvanSure assays. However, 6 allergens (Candida albicans, cheddar cheese, chicken, Cladosporium herbarum, pork, yeast)
in food panel and 4 allergens (dog, egg white, mackerel, soy bean) in inhalant panel showed no concordant positive result,
possibly due to rare frequency of specific IgE antibodies to these allergens among Koreans and restricted number of paired
samples in this study. On the contrary, two most common allergens in both food and inhalant panels which were Der-
matophagoides pteronyssinus and Dermatophagoides farina showed high total agreement percentages of over 95.0% and high
agreement levels with kappa indices over 0.9. However, total agreement percentage and kappa index decreased to 93.0%
and 0.8, respectively, for house dust, which was the third most common allergen.
3.3. Comparison of AdvanSure Allostation Smart II or PROTIA Allergy-Q with RIDA Allergy Screen applying cut-off level of class 2
We evaluated concordance rate of two newly developed fully automated assays (i.e. AdvanSure Allostation Smart II and
PROTIA Allergy-Q) with results by RIDA Allergy Screen considered as the reference values in this study utilizing class 2 for
the cut-off level for positive result (Table 4). Total agreement percentages were over 90.0% in most allergens in both assays
for food and inhalant panels. However, allergens with the most frequent positive results (i.e. D. farina, D. pteronyssinus,
house dust, and storage mite) presented concordance rates ranging from 69.6% to 90.0% for both AdvanSure Allostation
Smart II and PROTIA Allergy-Q in food panel as well as inhalant panel.
Furthermore, several allergens which showed propensity toward positive result in specific assay were noticed in both
comparison analyses (Table 5). While AdvanSure Allostation Smart II and PROTIA Allergy-Q showed positive propensity for
Table 5
List of allergens which present positive propensity in each assay.
Allergen AdvanSure SmartII vs. RIDA PROTIA Allergy-Q vs. RIDA
AdvanSure SmartII positive pro-
pensity (%)
RIDA positive propensity
(%)
PROTIA Allergy-Q positive pro-
pensity (%)
RIDA positive propensity
(%)
Food panel
Cockroach NS NS 7.5 NS
D. farinae 23.3 NS 17.5 NS
D. pteronyssinus 20.0 NS 10.0 NS
Dog NS NS 12.5 NS
House dust 26.7 NS NS NS
Pupa, silk cocoon 10.0 NS 10.0 NS
Storage mite 13.3 NS NS NS
Wheat flour NS NS 10.0 NS
Inhalant panel
Birch-alder mix NS NS 7.5 NS
Cat 8.9 NS NS NS
Crab NS NS 5.4 NS
D. farinae 22.8 NS 17.2 NS
D. pteronyssinus 24.1 NS 10.8 NS
House dust 30.4 NS 19.4 NS
Milk 6.3 NS NS 6.5
Storage mite 7.6 NS NS NS
NS: Not significant, defined as discrepant results less than 5%.
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allergens with 10% discrepant results. For evaluation of AdvanSure Allostation Smart II, three allergens with the highest
positive propensity results were D. farina (23.3%, 22.8%), D. pteronyssinus (20.0%, 24.1%), and house dust (26.7%, 30.4%) in
both food and inhalant panels. Similarly three highest positive propensity results for PROTIA Allergy-Q were observed in D.
farina (17.2%), D. pteronyssinus (10.8%), and house dust (19.4%) in inhalant panel. However, D. farina (17.5%) and dog (12.5%)
showed highest positive propensity results in food panel of PROTIA Allergy-Q. Interestingly, the allergen with largest class
difference between AdvanSure Allostation Smart II or PROTIA Allergy-Q and RIDA Allergy Screen was pupa silk cocoon in
food panel although it showed positive propensity of 10.0% (i.e. mean difference by class 3 in AdvanSure Allostation Smart II
vs. RIDA Allergy Screen comparison and mean difference by class 5 in PROTIA Allergy-Q vs. RIDA Allergy Screen
comparison).
3.4. Effects of lowering or raising up the cut-off level for positive result
To evaluate the effects of various cut-off levels for positive result determination, we applied two more cut-off levels other
than the conventional criteria of class 2 as minimal requirement for positive result; class 1 and class 3 as cut-off levels. Total
agreement percentages and concordant positive rates were fairly influenced by application of both higher and lower cut-off
levels (Figs. 1 and 2). Since higher cut-off level led to more negative results, concordant positive rates decreased naturally.
However, the changes of total agreement percentage according to the increase in cut-off level varied among allergens by
different analyzers.
3.5. Evaluation of positive rates for unique antigens in specific analyzer
Since different analyzers include various allergens, analyzer-specific allergens present diverse frequencies among patients
(Table 6). Among the accretional allergens introduced in Advansure Allostation Smart II, Acarus siro and apple in inhalant panel
showed significant positive rates of 20.0% and 8.9%, respectively, when class 1 was utilized as cut-off level. When cut-off level was
increased to class 2, these positive rates decreased to 12.2% and 4.4%, respectively (data not shown).
3.6. Frequency of multiple allergen positive results per patient by four different analyzers
Because multiple allergen positive results might indicate cross-reactivity between similar allergens, frequency of patients
with two or more positive results was analyzed according to four different analyzers. By application of class 2 as the cut-off
level for positive result, AdvanSure AlloScreen and AdvanSure Allostation Smart II presented highest frequency of patients
with multiple positive allergens (i.e. AdvanSure AlloScreen: N¼30 for food panel and N¼43 for inhalant panel, AdvanSure
Allostation Smart II: N¼23 for food panel and N¼37 for inhalant panel) with maximum positive allergen numbers of 23 and
34 in food panel and 28 and 32 in inhalant panel, respectively.
Fig. 1. Changes of total agreement percentage and concordant positive rate according to three different cut-off levels for positive result determination in
the food panels.
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During the last decade, there have been several remarkable introductions of new MAST assays by different manufacturers
into the clinical field of allergic diseases. Accordingly, evaluation and comparison studies of these novel MAST analyzers
were reported by few groups [6,8]. Until today, a total of four MAST assays [i.e. AdvanSure AlloScreen, RIDA Allergy Screen,
MAST Optigen (Hitachi), and Polycheck (Biocheck)] were frequently evaluated with each other and showed comparable
clinical performances [10,11,20]. Recently, Lee and colleagues presented favorable performance of newly developed PROTIA
Allergy-Q [12]. In this current trend, we evaluated four MAST analyzers including two newly developed and fully automated
assays. This study is the first evaluation report for AdvanSure Allostation Smart II and only the second comparison study for
PROTIA Allergy-Q. Also, our study is unique for evaluating upgraded version of specific assay to ensure the improvement by
including both AdvanSure AlloScreen and AdvanSure Allostation Smart II.
Based on our results, most results of comparison analyses presented good concordance levels by means of total
agreement percentages over 90.0%. Satisfactory agreements were observed not only in the comparison between AdvanSure
AlloScreen and AdvanSure Allostation Smart II, but also in the evaluation of AdvanSure Allostation Smart II and PROTIA
Allergy-Q compared with RIDA Allergy Screen. Although four allergens with the most frequent positive results, which were
D. farina, D. pteronyssinus, house dust, and storage mite, showed slightly lower concordance rates, these different results
could be sufficiently overcome by careful interpretation of MAST results in association with clinical manifestations.
One interesting finding we focused on in this study was positive propensity of each analyzer. In the midst of various
available MAST analyzers with comparable diagnostic performance, it is important for laboratory physicians to recognize the
unique propensity of each analyzer which might easily lead to positive results for particular allergen. Our study suggests
that AdvanSure Allostation Smart II and PROTIA Allergy-Q are more sensitive or prone to report positive results for three
common allergens (i.e. D. farina, D. pteronyssinus, and house dust) in both food and inhalant panels than RIDA Allergy
Screen. Considering the multiple positive result frequencies related with cross-reactivity among similar allergens as possible
mechanism for explanation [21–23], positive propensity of each analyzer should be cautiously understood. Moreover,
variations in the allergen extraction method by different manufacturers might have caused this phenomenon of diverse
positive propensity in each analyzer.
Fig. 2. Changes of total agreement percentage and concordant positive rate according to three different cut-off levels for positive result determination in
the inhalant panels.
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should be assessed based on evidences for continuous and dramatic changes in the environment and socio-behavioral
lifestyle of modern individuals [24,25]. At the same time, cost-effective approach is required for choices of clinically efficient
allergen with reference to epidemiologic results of geographically characteristic allergen studies [26–29]. Our results sup-
port the significant positive rate for Acarus siro among Korean population [30], which is unique allergen included only in
Advansure Allostation Smart II inhalant panel. Further investigations for Acarus siro as an inhalant allergen in general po-
pulation might highlight the advantage of Advansure Allostation Smart II.
One of the most important approaches we performed in this study was the re-evaluation of cut-off levels in order to
avoid false positive results. Besides the conventional cut-off level of class 2 as the minimal positive result criteria, we
analyzed the changes of total agreement percentages and concordant positive rates according to cut-off level decrease to
class 1 or increase to class 3. Although the increase of cut-off level seemed to make clinical circumstance more simple and
concise by presenting only the definitive positive allergens, this modification resulted in lower concordant positive rates
with possibility of missing potentially critical allergens. On the other hand, decrease of cut-off level produced lower total
agreement percentages in most allergens, which might obscure physicians from clear identification of clinically relevant
allergens. Detailed evaluation with similar approach for optimal cut-off class should be conducted for each analyzer ac-
cording to specific regional frequency and distribution of allergens in the future.
A critical limitation of this study was the use of RIDA Allergy Screen assay as the reference value for evaluation of newly
developed analyzers. Among the comparison studies published until today, most studies included the ImmunoCAP system
(Phadia, Uppsala, Sweden) for comparison analyses as an empirically reference method [8,10–12,20]. However, the Im-
munoCAP system is neither the official nor the definite reference procedure for measurement of allergen-specific IgE an-
tibodies despite its good reliability and reproducibility. While the ImmunoCAP system might be impractically expensive for
efficient clinical service for small to medium sized clinical laboratories [31], RIDA Allergy Screen assay has been con-
tinuously evaluated and reported for favorable clinical correlation with not only the ImmunoCAP system, but also serum
total IgE [10,32]. We anticipated that objective comparison between currently available MAST analyzers might provide
sufficient information for clinical use in the practical medical field.
Table 6
List of analyzer-specific allergens and frequencies of positive results using cut-off level of class 1.
Food panel Inhalant panel
AdvanSure Smart II PROTIA Allergy-Q RIDA AdvanSure Smart II PROTIA Allergy-Q RIDA
N¼40 N¼40 N¼40 N¼90 N¼93 N¼93
Allergen Positivity
frequency
(rate, %)
Allergen Positivity
frequency
(rate, %)
Allergen Positivity
frequency
(rate, %)
Allergen Positivity
frequency
(rate, %)
Allergen Positivity
frequency
(rate, %)
Allergen Positivity
frequency
(rate, %)
Alder 2 (5.0) Almond 2 (5.0) Chocolate 0 Acarus
siro
18 (20.0) Weat flour 3 (3.2) Anchovy 0
Celery 1 (2.5) Latex 0 Alder 2 (2.2) Banana 0
Cacao 0 Lilac 0 Apple 8 (8.9) Chestnut 1 (1.1)
Maize 1 (2.5) Redtop,
bent grass
0 Cacao 0 Chocolate 0
Mushroom 0 Wool 0 English
plantain
1 (1.1) Clam 0
Sesame 1 (2.5) Yellow
jacket
(wasp)
1 (2.5) Guinea
pig
0 Cucumber 2 (2.2)
Squid 2 (5.0) Hamster 0 Kiwi 1 (1.1)
Hinoki
cypress
1 (1.1) Lilac 1 (1.1)
Honey
bee
3 (3.3) Mango 0
Horse 3 (3.3) Mussel 0
Maize 1 (1.1) Wool 0
Sesame 1 (1.1)
Sheep 1 (1.1)
J.H. Rim et al. / Practical Laboratory Medicine 4 (2016) 50–6160In conclusion, AdvanSure Allostation Smart II maintained steady concordant performance in the upgrade process from
AdvanSure AlloScreen, with the uniquely extended allergen list including Acarus siro which showed certain positive rates.
AdvanSure Allostation Smart II and PROTIA Allergy-Q presented favorable agreement performances with RIDA Allergy
Screen, although positive propensities were noticed in some allergens. The conventional cut-off level of class 2 as the
minimal positive result criteria appeared to be suitable for current MAST analyzers in the clinical interpretation.Conflict of interest
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